Pharma Sector
-
{
- All
- News
- Videos
-
How A Rs 276 Stock Turned Into A Rs 20,000 Multibagger: Do You Own It?
A Rs 1 lakh investment in Neuland Laboratories at Rs 276 per share would be worth around Rs 72.5 lakh at Rs 20,000, excluding dividends, taxes, and transaction costs. The pharma company’s earnings growth and changing business profile help explain its multibagger journey.
-
Exclusive: After Survey Flags 2,800% Pharma Profit, Tukaram Mundhe Calls For Transparency
While pharma or any other industry will not work to incur losses, Tukaram Mundhe said there needs to be transparency. "A trade margin of 2800 per cent is not acceptable, either as a consumer or as a hospital or as a regulator," he told NDTV.
-
Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's Why
Shares of Cohance Lifesciences advanced in trade even after weak Q1 results, with the market taking comfort from the absence of data integrity observations in the USFDA inspection.
-
Novartis India Q1 Results: Profit At Rs 32 Crore; Revenue Up 19% To Rs 104 Crore
Novartis India Q1 net profit rose 16.7% to Rs 32.2 crore, while revenue increased 18.7% to Rs 104 crore. Ebitda jumped 29.2% year-on-year
-
From Pharmacy Of World To Innovation Hub: PM Modi Bats For India's Pharmaceutical Leap
New Delhi, April 14 (IANS) Prime Minister Narendra Modi on Tuesday said that India’s pharma sector is moving up from the pharmacy of the world to a hub of innovation.
-
From Pharmacy Of World To Innovation Hub: PM Modi Bats For India's Pharmaceutical Leap
New Delhi, April 14 (IANS) Prime Minister Narendra Modi on Tuesday said that India’s pharma sector is moving up from the pharmacy of the world to a hub of innovation.
-
Budget: NGOs Seek Higher Fund Allocation For Adolescents', Elderly's Health
NGOs have urged the government to increase the allocation of funds for health and nutrition for adolescents and elderly in the upcoming budget.
-
Budget 2022: Pharma Sector Seeks Greater Fund Allocation
The pharma industry is expecting an increase in the overall fund allocation for the healthcare sector, focus on policies that encourage R&D activities
-
Budget Fails To Cheer Healthcare Industry As Demands Unmet
Leading healthcare providers on Tuesday rued that the Budget has failed to address many of the long pending demands of the industry.
-
More Investment In R&D, Health Insurance Must Be Slotted In 5% GST Tax Slab
Budget 2021: Experts believe that for the long-term, the government must increase the investment for R&D, equipment, and medical infrastructure, to develop a stronger healthcare system
-
Government Doubles Healthcare Spending, Opens Up Insurance In 'Get Well Soon' Budget
Budget 2021: India, which has the world's second-highest coronavirus caseload after the United States, currently spends about 1 per cent of GDP on health, among the lowest for any major economy
-
Budget 2023: Centre Must Promote Research, Give Incentives To Boost Investment- Pharma Sector
The government is likely to retain its focus on the pharmaceutical sector in the upcoming Union Budget as India emerges from multiple waves of the coronavirus pandemic.
-
Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch s...
-
Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch s...
-
Pharma Companies May Report Strong Revenue Growth For Q1: Jefferies
The pharmaceuticals sector may report strong revenue growth for the first quarter of the current fiscal year, foreign brokerage Jefferies has said in a report.
-
How A Rs 276 Stock Turned Into A Rs 20,000 Multibagger: Do You Own It?
A Rs 1 lakh investment in Neuland Laboratories at Rs 276 per share would be worth around Rs 72.5 lakh at Rs 20,000, excluding dividends, taxes, and transaction costs. The pharma company’s earnings growth and changing business profile help explain its multibagger journey.
-
Exclusive: After Survey Flags 2,800% Pharma Profit, Tukaram Mundhe Calls For Transparency
While pharma or any other industry will not work to incur losses, Tukaram Mundhe said there needs to be transparency. "A trade margin of 2800 per cent is not acceptable, either as a consumer or as a hospital or as a regulator," he told NDTV.
-
Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's Why
Shares of Cohance Lifesciences advanced in trade even after weak Q1 results, with the market taking comfort from the absence of data integrity observations in the USFDA inspection.
-
Novartis India Q1 Results: Profit At Rs 32 Crore; Revenue Up 19% To Rs 104 Crore
Novartis India Q1 net profit rose 16.7% to Rs 32.2 crore, while revenue increased 18.7% to Rs 104 crore. Ebitda jumped 29.2% year-on-year
-
From Pharmacy Of World To Innovation Hub: PM Modi Bats For India's Pharmaceutical Leap
New Delhi, April 14 (IANS) Prime Minister Narendra Modi on Tuesday said that India’s pharma sector is moving up from the pharmacy of the world to a hub of innovation.
-
From Pharmacy Of World To Innovation Hub: PM Modi Bats For India's Pharmaceutical Leap
New Delhi, April 14 (IANS) Prime Minister Narendra Modi on Tuesday said that India’s pharma sector is moving up from the pharmacy of the world to a hub of innovation.
-
Budget: NGOs Seek Higher Fund Allocation For Adolescents', Elderly's Health
NGOs have urged the government to increase the allocation of funds for health and nutrition for adolescents and elderly in the upcoming budget.
-
Budget 2022: Pharma Sector Seeks Greater Fund Allocation
The pharma industry is expecting an increase in the overall fund allocation for the healthcare sector, focus on policies that encourage R&D activities
-
Budget Fails To Cheer Healthcare Industry As Demands Unmet
Leading healthcare providers on Tuesday rued that the Budget has failed to address many of the long pending demands of the industry.
-
More Investment In R&D, Health Insurance Must Be Slotted In 5% GST Tax Slab
Budget 2021: Experts believe that for the long-term, the government must increase the investment for R&D, equipment, and medical infrastructure, to develop a stronger healthcare system
-
Government Doubles Healthcare Spending, Opens Up Insurance In 'Get Well Soon' Budget
Budget 2021: India, which has the world's second-highest coronavirus caseload after the United States, currently spends about 1 per cent of GDP on health, among the lowest for any major economy
-
Budget 2023: Centre Must Promote Research, Give Incentives To Boost Investment- Pharma Sector
The government is likely to retain its focus on the pharmaceutical sector in the upcoming Union Budget as India emerges from multiple waves of the coronavirus pandemic.
-
Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch s...
-
Indian Pharma's Focus On Acquisitions To Limit Deleveraging: Fitch
New Delhi: In line with global trends in thepharmaceuticals sector, the focus of domestic drug firms on acquisitionsto consolidate their position will limit deleveraging for thetime being, rating agency Fitch has said. "The ongoing focus of the top Indian pharma companies' onselective acquisitions to limit deleveraging over the shortterm," Fitch s...
-
Pharma Companies May Report Strong Revenue Growth For Q1: Jefferies
The pharmaceuticals sector may report strong revenue growth for the first quarter of the current fiscal year, foreign brokerage Jefferies has said in a report.
